By Daniella Parra
Aktis Oncology said it appointed Akos Czibere, MD, PhD, as Chief Medical Officer.
Dr. Czibere has overseen several functional areas in his nearly 20-year career, filed a number of new drug applications and successfully led multiple global registration programs in solid tumors and hematological malignancies with approvals in the US, EU, Japan, China and other regions, the company said.
“Akos’ broad experience and deep expertise in oncology drug development and regulatory affairs further strengthens our capabilities to deliver on the significant patient impact potential of our first-in-class Nectin-4-targeted miniprotein radioconjugate, as well as the multiple programs to follow,” said Matthew Roden, PhD, President and Chief Executive Officer of Aktis. “We thank Pankaj for his contributions to Aktis and look forward to his continued impact as a member of our SAB.”
Dr. Czibere has also authored over 60 manuscripts in peer-reviewed journals, Aktis said.
Contact:
Editor@executives-edge.com
